Status:
UNKNOWN
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
Lead Sponsor:
Simon Williamson Clinic
Collaborating Sponsors:
Helsinn Healthcare SA
Conditions:
Chemotherapy Induced Nausea and Vomiting
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic...
Detailed Description
Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions. The emetogenicity of the chemotherapy administered and specifi...
Eligibility Criteria
Inclusion
- CHEMOTHERAPY NAIIVE
- patient receiving moderately or highly emetogenic chemotherapy
- lung cancer
- breast cancer
Exclusion
- PRIOR CHEMOTHERAPY for any cancer
- nausea or vomiting 24 hours prior to study entry
Key Trial Info
Start Date :
September 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06065722
Start Date
September 9 2023
End Date
December 31 2023
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rudolph M Navari
Mount Olive, Alabama, United States, 35117